Gábor Liposits

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

Gerald W. Prager, Marwan Fakih, Fortunato Ciardiello et al. · New England Journal of Medicine · 2023 · 428 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial

Stine Brændegaard Winther, Gábor Liposits, Halla Skúladóttir et al. · ˜The œLancet. Gastroenterology & hepatology · 2019 · 73 citations

Medicine, Geriatric Medicine, Oncology +14

Sixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment

Dave E. W. van der Kruijssen, Sjoerd G. Elias, Geraldine R. Vink et al. · JAMA Surgery · 2021 · 53 citations · Full text

Medicine, Oncology, Surgery +17

Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study.

Josep Tabernero, Gerald W. Prager, Marwan Fakih et al. · Journal of Clinical Oncology · 2023 · 48 citations · Full text

Medicine, Oncology, Pharmacology +12

Trifluridine–tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study

Thierry André, Alfredo Falcone, Yaroslav Shparyk et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 43 citations · Full text

Medicine, Oncology, Pharmacology +10